<DOC>
	<DOCNO>NCT01336062</DOCNO>
	<brief_summary>Gastric cancer poor prognosis majority patient resistant 5-FU/DDP base first-line chemotherapy China . There recommended second-line chemotherapy advance gastric cancer . Taxane promise gastric cancer . Nanoparticle Albumin-Bound Paclitaxel ( Abraxane，ABI-007 ) good convenience use approve breast cancer many country . The investigator initiate prospective phase Ib/IIa clinical trial nab-paclitaxel plus TS-1 second-line treatment advance gastric cancer observe safety efficacy .</brief_summary>
	<brief_title>Trial ABI-007 Plus S-1 Second-line Chemotherapy Advanced Gastric Cancer Patients</brief_title>
	<detailed_description>This study two-stage design . Stage 1 The investigator evaluate two recommend dose tolerability nab-paclitaxel plus S-1 one course treatment 3+1 design : nab-paclitaxel give intravenously day 1 8 dose follow , Treatment repeat every 3 week : Treatment arm A：125 mg /m2 ; Treatment arm B：100 mg /m2 ; Treatment arm C : 80 mg /m2 ; S-1 give orally twice day follow 14 consecutive day , follow 1-week rest . Treatment repeat every 3 week . BSA ＜ 1.5 m2，40mg，bid ; BSA ≥ 1.5 m2，50mg，bid . The investigator determine whether continue original regimen ; compare safety pharmacokinetic result original profile combination therapy select best therapy program ( RD , recommend dose ) . Stage 2 According two-stage design ( Simon,1989 ) , re-entry subject recommend dose group total 25 valid case . If 11 patient achieve response , enter second phase total 66 patient .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>1 . Signed informed consent form 2 . Age 1875 year ; 3 . Histologically cytologically confirm gastric cancer ; 4 . Advanced recurrent , metastatic disease ; 5 . Performance Status Eastern Cooperative Oncology Group ( ECOG ) 01 ; 6 . Life expectancy least 12 week ; 7 . At least one measurable disease ( accord RECIST , Response Evaluation Criteria Solid Tumors ) 8 . Subjects receive one prior regimen gastric carcinoma develop disease progression recurrence within 6 month end systemic adjuvant treatment . The regimen must contain fluorouracil ( e.g . 5FU , capecitabine ) and/or cisplatin ; 9 . Haematopoietic status : Absolute neutrophil count &gt; 1.5 x 109/L , Platelet count &gt; 90 x 109/L , Hemoglobin least 9 g/dl , 10 . Hepatic status : Bilirubin ≤ 1.5 x upper limit normal ( ULN ) , AST ALT ≤ 2.5 time ULN ( liver metastasis ) , ≤5 time ULN ( liver metastasis ) 11 . Renal status : Creatinine ≤1.5 time ULN calculate creatinine clearance , use CockcroftGault formula , ≥40 mL/min ; 12 . Able swallow retain oral medication；without malabsorption syndrome , disease significantly affect gastrointestinal function , ulcerative colitis Crohn 's disease ; 13 . Cardiovascular : Baseline LVEF 50 % measure echocardiography ( ECHO ) ; 14 . Negative serum pregnancy test ( For woman childbearing potential ) ; Fertile patient must use effective contraception . 1 . Received prior treatment include taxane S1 ; 2 . Concurrent systemic anticancer therapy ( immunotherapy , biologic therapy , hormone therapy , etc ) ; receive treatment investigational agent participation another therapeutic clinical trial within 4 week ; 3 . Unresolved unstable , serious toxicity prior cancer treatment ( toxicity great grade 2 ; peripheral neuropathy grade 2 great 4 . Symptomatic brain metastasis ; 5 . Known history uncontrolled symptomatic angina , clinically significant arrhythmia , congestive heart failure , uncontrolled hypertension ( ≥ 180/110 ) , unstable diabetes mellitus , dyspnea rest , chronic therapy oxygen ; 6 . History malignancy . However , subject past current history completely resect basal squamous cell carcinoma skin successfully treat situ carcinoma cervix eligible 7 . Dementia , alter mental status , psychiatric condition would prevent understand render ICF ; 8 . Active uncontrolled infection ; 9 . Concurrent treatment investigational agent participation another therapeutic clinical trial ; 10 . Pregnant lactating woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2015</verification_date>
	<keyword>advanced</keyword>
	<keyword>resistant prior chemotherapy</keyword>
</DOC>